2017
DOI: 10.1007/s40264-017-0505-6
|View full text |Cite
|
Sign up to set email alerts
|

Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns

Abstract: Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals, especially when used in combination with other behavioural preventive methods. Safety concerns about PrEP present challenges in the implementation and use of PrEP. The aim of this review is to discuss safety concerns observed in completed clinical trials on the use of PrEP. We performed a literature search on PrEP in PubMed, global … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
38
0
9

Year Published

2017
2017
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 64 publications
(49 citation statements)
references
References 40 publications
2
38
0
9
Order By: Relevance
“…For example, patients may benefit from an explicit justification about testing frequency and to reassure patients that FTC/TDF is a safe medication. [30][31][32] Our study has several limitations. First, the qualitative design permits us to describe these findings as transferable but not generalizable.…”
Section: Discussionmentioning
confidence: 95%
“…For example, patients may benefit from an explicit justification about testing frequency and to reassure patients that FTC/TDF is a safe medication. [30][31][32] Our study has several limitations. First, the qualitative design permits us to describe these findings as transferable but not generalizable.…”
Section: Discussionmentioning
confidence: 95%
“…The most general side effects associated with PrEP in uninfected individuals include headache, abdominal pain, weight loss, nausea, dizziness, vomit, and diarrhea (Tetteh et al, 2017;Desai et al, 2017). Some symptoms disappear after a while.…”
Section: Side Effects Of Prepmentioning
confidence: 99%
“…Advances in preventive measures for HIV have led to the use of ART by HIV-uninfected persons to prevent the acquisition of HIV, which is known as pre-exposure prophylaxis (PrEP) 2. PrEP consists of a daily oral regimen of tenofovir alafenamide and emtricitabine 3–5. PrEP has been shown to reduce the risk of acquisition of HIV 2 4.…”
Section: Introductionmentioning
confidence: 99%